PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17656665-9	2007	Among studied drugs only fenofibrate increased HDL-associated Lp-PLA2 (HDL-Lp-PLA2) activity and mass attributable to a preferential increase in Lp-PLA2 associated with the HDL-3c subfraction.	Fenofibrate	25-36	HDL3	Homo sapiens	173-178	
12462290-9	2002	The amount of HDL3 increased significantly with fenofibrate compared with placebo (P < 0.001).	Fenofibrate	48-59	HDL3	Homo sapiens	14-18	
12462290-12	2002	CONCLUSION: Taken together, these findings indicate that fenofibrate therapy increased the HDL subfraction with the smallest diameter (HDL3), which is largely responsible for withdrawing cholesterol from peripheral cells.	Fenofibrate	57-68	HDL3	Homo sapiens	135-139	
11282093-5	2001	Fenofibrate did not change LpAI level but had an effect on LpAI particle distribution among HDL(2) and HDL(3) increasing LpAI concentration in HDL(2) and slightly decreasing LpAI concentration in HDL(3).	Fenofibrate	0-11	HDL3	Homo sapiens	103-109	
11282093-5	2001	Fenofibrate did not change LpAI level but had an effect on LpAI particle distribution among HDL(2) and HDL(3) increasing LpAI concentration in HDL(2) and slightly decreasing LpAI concentration in HDL(3).	Fenofibrate	0-11	HDL3	Homo sapiens	196-202	
3709644-4	1986	Administration of fenofibrate alone resulted in decreases in VLDL and LDL cholesterol (-48% and -18%) and in serum apolipoprotein B (-10%), but in increases in HDL, HDL2, and HDL3 (+25%, +26%, and +24%), and in serum apolipoprotein A-I (+6%).	Fenofibrate	18-29	HDL3	Homo sapiens	175-179